Compare SPCE & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | VYGR |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.9M | 232.4M |
| IPO Year | N/A | 2015 |
| Metric | SPCE | VYGR |
|---|---|---|
| Price | $3.86 | $4.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $10.60 | ★ $16.17 |
| AVG Volume (30 Days) | ★ 3.0M | 468.8K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,661,000.00 | ★ $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,908.26 | $107.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.18 | $2.65 |
| 52 Week High | $7.59 | $7.44 |
| Indicator | SPCE | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 57.14 | 43.85 |
| Support Level | $3.20 | $3.91 |
| Resistance Level | $3.79 | $4.30 |
| Average True Range (ATR) | 0.25 | 0.25 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 97.79 | 46.61 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.